Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; sodium lauryl sulfate; cetyl alcohol - short-term treatment of bacterial infections at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms: skin and skin structure infections. urinary tract infections (complicated and uncomplicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablet preparations. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections cause by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxycillin/clavulanic acid tablet preparations should not require the addition of another antibiotic due to the amoxycillin content of these products.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; sodium lauryl sulfate; cetyl alcohol - short-term treatment of bacterial infections at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms: skin and skin structure infections. urinary tract infections (complicated and uncomplicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablet preparations. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections cause by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxycillin/clavulanic acid tablet preparations should not require the addition of another antibiotic due to the amoxycillin content of these products.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 573.921 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: croscarmellose sodium; titanium dioxide; sodium lauryl sulfate; microcrystalline cellulose; gelatin; iron oxide black; magnesium stearate; colloidal anhydrous silica; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli. respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli. genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 286.96 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; sodium lauryl sulfate; gelatin; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli. respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli. genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate (equivalent: amoxicillin, qty mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriologic studies including sensitivity tests and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative agent has yet to be identified. respiratory tract infections (acute and chronic): h, influenzae; streptococcus; s. pneumoniae; staphylococcus, non-pencillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e, coli (see microbiology); p. mirabilis; s. faecalis. gonorrhoea (n.gonorrhoeae, non-penicillinase producing). skin and skin structure infections: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). prophylaxis of endocarditis. amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate (equivalent: amoxicillin, qty mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; iron oxide yellow; titanium dioxide; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriologic studies including sensitivity tests and by clinical response. amoxycillin, alone or in combination with another antibiotic, may be used in an emergency where the causative agent has yet to be identified. respiratory tract infections: (acute and chronic): h.influenzae; streptococcus; s.pneumoniae; staphylococcus, non-penicillinase producing; e.coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic) e.coli (see microbiology); p.mirabilis; s.faecalis. gonorrhoea (n.gonorrhoeae, non-penicillinase producing). skin and skin structure infections: staaphylococcus, non-penicillinase producing: streptococcus: e.coli (see microbiology). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathgogens with established pencicillin g susceptibility should be preferentially treated with penicillin g.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - amoxicillin trihydrate - oral capsule - 500mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - amoxicillin trihydrate - oral capsule - 500mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - amoxicillin trihydrate - oral capsule - 500mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - amoxicillin trihydrate - oral capsule - 500mg